Vaginal health in contraceptive vaginal ring users-A review

European Journal of Contraception and Reproductive Health Care

Volumn 18, Issue 4, 2013, Pages 234-241

  Lete, Iñaki ^a,b   Cuesta, María C ^a   Marín, Juan M ^a,b   Guerra, Sandra ^a  

^a HOSPITAL TXAGORRITXU   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Colposcopy; Contraceptive vaginal ring; Cytology; Vaginal health; Vaginal infections

Indexed keywords

ELCOMETRINE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHYLENE VINYL ACETATE COPOLYMER; ETONOGESTREL; MICONAZOLE; ORAL CONTRACEPTIVE AGENT; SILASTIC;

BACTERIAL FLORA; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; COLPOSCOPY; CONTRACEPTION; CYTOLOGY; HUMAN; IN VITRO STUDY; LACTOBACILLUS ACIDOPHILUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES CEREVISIAE; SEXUAL INTERCOURSE; SYSTEMATIC REVIEW; VAGINA; VAGINA DISCHARGE; VAGINA EPITHELIUM; VAGINA FLORA; VAGINA RING; VAGINAL DISCOMFORT; VAGINITIS;

EID: 84880261826     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2013.801954     Document Type: Review

References (52)

1. Dzuik P , Cook B. Passage of steroids through silicone rubber. Endocrinology 1966;78:208-11.
2. Ballagh S A, Mishell D R Jr, Lacarra M , et al. A contraceptive vaginal releasing norethindrone acetate and ethinyl estradiol. Contraception 1994;50:517-33.
3. Shastri P V. Toxicology of polymers for implant contraceptives for women. Contraception 2002;65:9-13. (Pubitemid 34175233)
4. Wieder DR , Pattimakiel L. Examining the effi cacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing ® ). Int J Womens Health 2010;2:401-9.
5. Mansour D , Inki P , Gemzell-Danielsson K. Effi cacy of contraceptive methods: A review of the literature. Eur J Contracept Reprod Health Care 2010;Suppl. 2: S19-31.
6. Lete I , Doval JL, Pé r ez-Campos E , e t al. Factors affecting women ' s selection of a combined hormonal contraceptive method: The TEAM-06 Spanish cross-sectional study. Contraception 2007;76:77-83. (Pubitemid 47090168)
7. Roumen FJME. The contraceptive vaginal ring compared with the combined oral contraceptive pill: A comprehensive review of randomized controlled trials. Contraception 2007;75:420-9. (Pubitemid 46764299)
8. Maheux-Lacroix S, Leboeuf M, Dufresne A, Dodin S. Adolescent ' s willingness to use the contraceptive vaginal ring. J Obstet Gynaecol Can 2011;33:353-60.
9. Moher D , L iberati A , T etzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med 2009;6(7):e1000097. doi:10.1371/journal. pmed100097.
10. Roy S, Wilkins J, Mishell DR Jr. The effect of a contraceptive vaginal ring and oral contraceptives on the vaginal fl ora. Contraception 1981;24:481-91. (Pubitemid 12239515)
11. S chwan A, Ahren T, Victor A. Effects of contraceptive vaginal ring treatment on vaginal bacteriology and cytology. Contraception 1983;28:341-7. (Pubitemid 14215941)
12. Dieben T OM, Roumen FJ, Apter D. Effi cacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002;100:585-93. (Pubitemid 35246150)
13. Miller L , MacFarlane S A, Materi H L. A scanning electron microscopic study of the contraceptive vaginal ring. Contraception 2005;71:65-7. (Pubitemid 41583152)
14. Camacho D P , Consolaro M EL, Patussi E V , et al. Vaginal yeast adherence to the combined contraceptive vaginal ring (CCVR). Contraception 2007;76:439-43. (Pubitemid 350180732)
15. Chassot F , Camacho D P , Patussi E V , et al. Can L actobacillus acidophilus infl uence the adhesion capacity of Candida albicans on the combined contraceptive vaginal ring? Contraception 2010;81:331-5.
16. Veres S , Miller L , Burington B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol 2004;104:555-63. (Pubitemid 40458845)
17. Oddsson K , Leifels-Fischer B , de Melo N R, et al. Effi-cacy and safety of a contraceptive vaginal ring (NuvaRing ® ) compared with a combined oral contraceptive: A 1-year randomized trial. Contraception 2005;71:176-82. (Pubitemid 40250198)
18. Merki-Feld G S, Hund M. Clinical experience with the contraceptive vaginal ring in Switzerland, including a subgroup analysis of previous hormonal contraceptive use. Eur J Contracept Reprod Health Care 2010;15:413-22.
19. Fine PM, Tryggestad J, Meyers NJ, Sangi-Haghpeykar H. Safety and acceptability with the use of a contraceptive vaginal ring after surgical or medical abortion. Contraception 2007;75:367-71. (Pubitemid 46551074)
20. Archer D , Raine T, Darney P. An open-label noncomparative study to evaluate the vagina and cervix of NuvaRing ?users Fertil Steril 2002;76 (Suppl. 1):S25.
21. Roumen FJME, Boon ME, van Velzen D , et al. The cervico-vaginal epithelium during 20 cycles ' use of a combined contraceptive vaginal ring. Hum Reprod 1996;11:2443-8. (Pubitemid 27007452)
22. Bounds W , S zarewski A , L owe D , G uillebaud J. P reliminary report of unexpected local reactions to a progestogenreleasing contraceptive vaginal ring. Eur J Obstet Gynecol Reprod Biol 1993;48:123-5. (Pubitemid 23108943)
23. Fraser IS , Lacarra M, Mishell DR , et al. Vaginal epithelial surface appearances in women using vaginal rings for contraception. Contraception 2000;61:131-8. (Pubitemid 30236334)
24. Roumen FJME, Apter D , Mulders TMT, Dieben TOM. Effi cacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001;16:469-75. (Pubitemid 32218795)
25. Lete I , Sá nchez R , Haya J. Estudio de efi cacia y tolerabilidad del anillo vaginal NuvaRing ?en anticoncepci ó
26. k A, de la Loge C, Abetz L, van der Meulen EA. The combined contraceptive vaginal ring, NuvaRing ® :An international study of user acceptability. Contraception 2003;67:187-94. (Pubitemid 36255655)
27. Vijayaletchumi T, Siraj HH, Azmi MT, Jamil MA. Acceptability of contraceptive vaginal ring (NuvaRing ?) amongst nurses in a Malaysian teaching hospital. BJOG 2012;119:147.
28. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: Collaborative reanalysis of individual data for 16,753 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007;370:1609-21.
29. Sobel J D. Vaginitis. N Engl J Med 1 997; 337: 1896-903. (Pubitemid 28053998)
30. Verhoeven CHJ, van den Heuvel MW, Mulders TMT, Dieben TOM. The contraceptive vaginal ring, Nuva Ring ® , and antimycotic co-medication. Contraception 2004;69:129-32. (Pubitemid 38167462)
31. Haring T , Mulders T MT. The combined contraceptive ring NuvaRing ® and spermicide co-medication. Contraception 2003;67:271-2. (Pubitemid 36398509)
32. Verhoeven CHJ, Dieben TOM. The combined contraceptive vaginal ring, NuvaRing ® , and tampon co-usage. Contraception 2004;69:197-9. (Pubitemid 38224217)
33. Ahrendt HJ, Nisand I , Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing ® , compared with an oral contraceptive containing 30 mcg of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006;74:451-7. (Pubitemid 46043314)
34. Sabatini R, Cagiano R. Comparison profi les of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception 2006;74:220-3. (Pubitemid 44175362)
35. Bjarnadottir R, Tuppurainen M, Killick S. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol 2002;186:389-95. (Pubitemid 34234146)
36. van Laarhoven JAH, Kruft MAB, Vromans H. In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring. Int J Pharm 2002;232;163-73. (Pubitemid 34076762)
37. Lopez LM, G rimes DA , Gallo MF, Schulz KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev 2010;3:CD003552. doi:10.10002/14651858.CD003552.pub3 38.
38. Valore EV , Park CH, Igreti SL, Ganz T. Antimicrobial components of vaginal fl uid. Am J Obstet Gynecol 2002;78:167-9.
39. Sobel J, Chaim W. Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis. J Clin Microbiol 1996;34:2497-9. (Pubitemid 26307799)
40. Mead PB. Epidemiology of bacterial vaginosis. Am J Obstet Gynecol 1993;169:446-9. (Pubitemid 23259053)
41. Shoubnikova M, Hellberg D , Nilsson S, et al. Contraceptive use in women with bacterial vaginosis. Contraception 1997;55:355-8. (Pubitemid 27323512)
42. Rifkin S B, Smith M R, Brotman R M, et al. Hormonal contraception and risk of bacterial vaginosis diagnosis in an observational study of women attending STD clinics in Baltimore, MD. Contraception 2009;80:63-7.
43. Riggs M , Klebanoff M , Nansel T , et al. L ongitudinal association between hormonal contraceptives and bacterial vaginosis in women of reproductive age. Sex Transm Dis 2007;34:954-9. (Pubitemid 350158844)
44. De Seta F , Restaino S , De Santo D , et al. Effects of hormonal contraception on vaginal fl ora. Contraception 2012;86:526-9.
45. O ' Neill E , Reeves MF, Creinin MD. Baseline colposcopic fi ndings in women entering studies on female vaginal products. Contraception 2008;78:162-6.
46. Rock JA, Thompson JD. TeLinde' s operative gynecology, 8th edn. Philadelphia, PA: Lipincott-Raven 1977:501-28.
47. L ete I , Due ñ as JL, Esplugues JV, Martí-Cabrera M. Is the vagina an adequate route for the administration of hormonal contraceptives? Current Drug Metabol 2010;11:839-49.
48. Branhart KT, Timbers K , Pretorius ES, et al. In vivo assessment of NuvaRing ?placement. Contraception 2005;72:196-9.
49. Roumen FJME; Dieben TOM. Clinical acceptability of an ethylene-vinyl-acetate nonmedicated vaginal ring. Contraception 1999;59:59-62. (Pubitemid 29174417)
50. Ronco G , van Ballegooijen M , Becker N , et al. Prevalence of cervical intraepithelial neoplasia in patients with atypical squamous cells of undetermined signifi-cance from cervical pap smears in Beijing. Eur J Gynaecol Oncol 2011;32:411-4.
51. Harris TG, Miller L, Kulasingam S L, et al. Depotmedroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection. Am J Obstet Gynecol 2009;200:489:e1-8.
52. Frega A , Scardamaglia P , Piazze J , et al. Oral contraceptives and recurrence of human papillomavirus lesions and cervical intraepithelial neoplasia following treatment. Int J Gynaecol Obstet 2008;100:175-8.